69048-70-0

Usage

Uses

Used in Pharmaceutical Industry:
Dimethyl 4-nitroisophthalate serves as a key building block in the synthesis of pharmaceuticals. Its unique structure allows for the development of a range of medicinal compounds, contributing to the advancement of healthcare and therapeutic options.
Used in Polymer Industry:
In the polymer industry, dimethyl 4-nitroisophthalate is employed as a crucial component in the production of specific types of polymers. Its integration into polymer formulations can enhance properties such as strength, flexibility, and durability, catering to diverse applications.
Used in Dye Industry:
Dimethyl 4-nitroisophthalate is utilized in the dye industry for the preparation of various dyes. Its chemical properties enable the creation of dyes with distinct color characteristics and improved performance, meeting the demands of different industries.
Used in Liquid Crystal Display (LCD) Industry:
dimethyl 4-nitroisophthalate also plays a significant role in the production of liquid crystal display materials. Its incorporation into LCD technologies can enhance the display's visual quality and contribute to the development of advanced electronic devices.
Safety Note:
Dimethyl 4-nitroisophthalate should be handled and stored according to standard chemical safety procedures to ensure the safety of individuals and the environment.

Upstream product

• 67-56-1 methanol 
• 4315-09-7 4-nitroisophthalic acid 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 89-87-2 2,4-dimethylnitrobenzene 
• 74-88-4 methyl iodide 

Downstream Products

• 67667-50-9 Dimethyl-4-phenylthioisophthalat 
• 67666-73-3 4-Benzylsulfanyl-isophthalic acid dimethyl ester 
• 53063-31-3 4-phenoxy-1,3-benzenedicarboxylic acid dimethyl ester 

Relevant academic research and scientific papers

SELF-IMMOLATIVE SYSTEMS

The present invention is concerned with self-immolative recognition and/or responsive systems for electrophilic compounds, especially alkylating agents, which systems may comprise disclosure or detection of the alkylating agent. The present invention is especially concerned with non-protic triggered self-immolative systems, molecules, and methods, and in particular for detection of non- protic electrophilic agents, and especially alkylating agents, for example alkyl or benzylic halides, which may be found in pesticides or fumigants, or chemical warfare agents.

Discovery of Novel Pyrazole-Quinazoline-2,4-dione Hybrids as 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors

4-Hydroxyphenylpyruvate dioxygenase (HPPD, EC 1.13.11.27) has been identified as one of the most significant targets in herbicide discovery for resistant weed control. In a continuing effort to discover potent novel HPPD inhibitors, we adopted a ring-expansion strategy to design a series of novel pyrazole-quinazoline-2,4-dione hybrids based on the previously discovered pyrazole-isoindoline-1,3-dione scaffold. One compound, 3-(2-chlorophenyl)-6-(5-hydroxy-1,3-dimethyl-1H-pyrazole-4-carbonyl)-1,5-dimethylquinazoline-2,4(1H,3H)-dione (9bj), displayed excellent potency against AtHPPD, with an IC50 value of 84 nM, which is approximately 16-fold more potent than pyrasulfotole (IC50 = 1359 nM) and 2.7-fold more potent than mesotrione (IC50 = 226 nM). Furthermore, the co-crystal structure of the AtHPPD-9bj complex (PDB ID 6LGT) was determined at a resolution of 1.75 ?. Similar to the existing HPPD inhibitors, compound 9bj formed a bidentate chelating interaction with the metal ion and a π-πstacking interaction with Phe381 and Phe424. In contrast, o-chlorophenyl at the N3 position of quinazoline-2,4-dione with a double conformation was surrounded by hydrophobic residues (Met335, Leu368, Leu427, Phe424, Phe392, and Phe381). Remarkably, the greenhouse assay indicated that most compounds displayed excellent herbicidal activity (complete inhibition) against at least one of the tested weeds at the application rate of 150 g of active ingredient (ai)/ha. Most promisingly, compounds 9aj and 9bi not only exhibited prominent weed control effects with a broad spectrum but also showed very good crop safety to cotton, peanuts, and corn at the dose of 150 g of ai/ha.

Quinazolin-2,4-dione derivative and preparation method and application thereof

The invention provides a quinazolin-2,4-dione derivative and a preparation method and application thereof, and specifically, the invention provides a quinazolin-2,4-dione derivative shown as formula (I) and a composition comprising same. The invention further provides the method for preparing the derivative and the application of the derivative in selectively controlling unexpected plants among useful crops, wherein Q, W, Z, Y, R, R and R have the meanings as described by the invention. The formula (I) is as shown in the description below.

Triketone-based compound preparation method

The invention relates to the field of preparation of pesticides, and discloses a triketone-based compound preparation method, wherein the triketone-based compound has a structure represented by a formula (1). The method comprises that 1) a compound represented by a formula (2), 1,3-cyclohexanedione and CO are subjected to a reaction in the presence of a first catalyst under an alkali condition toobtain a product represented by a formula (3); and 2) the product represented by the formula (3) contacts a second catalyst and an alkali substance under a rearrangement reaction condition to obtain the triketone-based compound represented by the formula (1). According to the present invention, with the method, the triketone-based compound can be obtained in the low-cost and high-yield manner; andthe purity of the triketone-based compound obtained through the method is high. The formulas (1), (2) and (3) are defined in the specification.

Quinolinone compound and application thereof in drugs

The invention relates to a quinolinone compound and application thereof in drugs, particularly relates to a novel quinolinone compound, a pharmaceutical composition thereof and use of the compound or the pharmaceutical composition in preparing drugs. The drug is used for protecting, disposing, treating or alleviating HIF-related and/or EPO-related diseases of patients, wherein the HIF-related and/or EPO-related diseases comprise anemia, vascular diseases, regional myocardial ischaemia, metabolic disturbance, wound healing and the like.

TRIKETONE COMPOUND AND PREPARATION METHOD AND USE THEREOF

Disclosed in the present invention is a triketone compound which has a structure shown in Formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by Formula (I), which comprise that under the rearrangement reaction conditions, the compound having a structure as shown by Formula (II) is contacted with a catalyst in the presence of a base and a solvent. Further disclosed in the present invention is the use of a triketone compound having a structure as shown by Formula (I) in preventing and controlling weeds. Said triketone compound having a structure as shown by formula (I) in the present invention has the effect of preventing and controlling weeds, in particular having an excellent effect on preventing and controlling broadleaved weeds and/or gramineae weeds.

Rationally designed cooperatively enhanced receptors to magnify host-guest binding in water

When disengaged interactions within a receptor are turned on by its guest, these intrahost interactions will contribute to the overall binding energy. Although such receptors are common in biology, their synthetic mimics are rare and difficult to design. By engineering conflictory requirements between intrareceptor electrostatic and hydrophobic interactions, we enabled complementary guests to eliminate the "electrostatic frustration" within the host and turn on the intrahost interactions. The result was a binding constant of Ka >105 M-1 from ammonium-carboxylate salt bridges that typically function poorly in water. These cooperatively enhanced receptors displayed excellent selectivity in binding, despite a large degree of conformational flexibility in the structure.

Synthesis and herbicidal evaluation of triketone-containing quinazoline-2,4-diones

Exploring novel 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27, HPPD) inhibitors is one of the most promising research directions in herbicide discovery. To discover new triketone herbicides with broad-spectrum weed control as well as excellent crop selectivity, a series of (total 52) novel triketone-containing quinazoline-2,4-dione derivatives were synthesized and further bioevaluated. The greenhouse testing indicated that many of the newly synthesized compounds showed better or excellent herbicidal activity against broadleaf and monocotyledonous weeds at the dosages of 37.5-150 g of active ingredient (ai)/ha. The structure and activity relationship in this study indicated that the triketone-containing quinazoline-2,4-dione motif has possessed great impact on herbicide activity and may be used for further optimization. Among the new compounds, III-b and VI-a-VI-d displayed a broader spectrum of weed control than mesotrione. In addition, the compound III-b also demonstrated comparatively superior crop selectivity to mesotrione, thus possessing great potential for weed control in the field.

2 -AMINOQUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USES

A compound of formula (I) wherein X is NH2or OH and W is -C(O)-O- or -O-C(O)-; use thereof as a medicament, in particular for the treatment of inflammation, autoimmune disorder, immunogenic rejection reactions and cancer and for non-surgical abortion.

CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I Z-L-R1-Q-D-(V1)m-R2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R1, Q, D, V1, m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.